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http://dx.doi.org/10.1016/j.jmii.2013Background/purpose: The narrow spectrum of action of most bacteriocins is an important lim-
itation for their application as antimicrobial agents. The current study describes a novel
bacteriocin-like inhibitory substance (BLIS) that display extended spectrum antimicrobial ac-
tivity against vancomycin-resistant Enterococcus (VRE) strains.
Methods: Acquired resistance profiles of Enterococcus isolates determined based on the European
Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Preven-
tion (CDC) definition as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug
resistant (PDR). BLIS activity of Enterococcus isolates was investigated against Enterococcus fae-
calis (E. faecalis) ATCC 29212 as the indicator strain and clinical isolates including VRE,methicillin
resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria containing Pseudomonas aer-
uginosa (P. aeruginosa), Klebsiella, Acinetobacter, and Escherichia coli (E. coli).seases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Jomhori Eslami
he Tahere Research Center, Isfahan, Iran.
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372 D. Shokri et al.Results: Among 273 Enterococcus isolates, 27 and 2 VRE isolates, respectively, were XDR and PDR
and eight isolates had BLIS activity against the indicator strain. One of these isolates, identified as
E. faecium strain DSH20 based on its phenotypical and biochemical properties, as well as its 16S
rRNA gene sequence, had potent BLIS production against all 29 VRE strains, but had no activity
against MRSA, P. aeruginosa, Klebsiella, Acinetobacter, and E. coli strains. It was heat stable up
to 121C for 15 minutes (autoclave condition), active within the pH range of 3e9 and had UV sta-
bility, but its activity disappeared by treatment with proteinase K, pepsin, and trypsin, demon-
strating its proteinaceous nature. It was designated as an approximately 35 kDa peptide using
the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) method.
Conclusion: This peptide is a potential agent for use as an alternative antibacterial agent for the
treatment of drug-resistant strains of VRE infection.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Table 1 Antimicrobial categories and agents used to
define pandrug resistant (PDR), extensively drug-resistant
(XDR) and multidrug-resistant (MDR) in Enterococcus spp3




Streptomycin Streptomycin (high level)Introduction
The appearance and spread of antibiotic-resistant bacteria
are serious problems in public health worldwide.1,2 For
example, pandrug-resistant (PDR) isolates were defined as
non-susceptible to all agents in all antimicrobial categories
based on the European Centre for Disease Prevention and
Control (ECDC) and the Centers for Disease Control and
Prevention (CDC) definitions.3 Therefore, these strains that
are resistant to all tested antibiotic agents lead to curative
failure of therapy and are serious threats to the patient’s
safety. Vancomycin-resistant Enterococcus (VRE) has
developed a resistance to most commonly used antibiotics
and there are currently very few antibiotics that can be
used to treat these infections. New strategies for control-
ling these bacteria are urgently needed and the discovery
of new antimicrobial agents, such as bacteriocin and
bacteriocin-like inhibitory substance (BLIS), may help in
keeping down the development of these infections.1 Bac-
teriocins, secondary metabolites produced by various mi-
croorganisms, have bactericidal activity directed against
species that are usually closely related to the producer
microorganisms.4e6 One of the critical limitations to the use
of bacteriocins as antimicrobial and biopreservative agents,
is their narrow spectrum of action.7 The objective of this
study was the isolation and characterization of broad



















Characterization and identification of bacteria
from clinical specimens
Bacteria recovered from clinical specimens were identified
by standard biochemical methods.8 The samples were
cultured on blood agar (purchased from Himedia Company,
Mumbai, Vadhani Industrial Estate, India), the plates were
incubated at 35C for 24 hours and the pure isolates were
characterized and identified according to Gram stains and
biochemical tests, such as catalase reaction, presence of
pyrrolidonyl arylamidase (PYR), growth on bile aesculin
agar and 6.5% NaCl media.Antimicrobial categories and agents used to define
acquired resistance profiles in Enterococcus sp.
To define the acquired resistance profiles of Enterococcus
isolates, antimicrobial categories and agents were used as
shown in Table 1, according to ECDC and CDC definition.3
A multidrug-resistant (MDR) isolate was defined as being
non-susceptible to at least one agent in three or more
antimicrobial categories. An extensively drug-resistant
(XDR) isolate was defined as being non-susceptible to at
least one agent in all but two or fewer antimicrobial cat-
egories (i.e., bacterial isolates remain susceptible to only
one or two categories). Non-susceptibility to all agents in
all antimicrobial categories (i.e., no agents tested as sus-
ceptible) was defined as PDR Enterococcus. Thus, a bacte-
rial isolate that is characterized as XDR will also be
characterized as MDR and similarly, an XDR bacterial isolate
BLIS active against VRE 373would have to be further defined as PDR. For example, an
isolate that is just sensitive to gentamicin (belongs to the
aminoglycosides category), imipenem (belongs to the car-
bapenems category) and linezolid (belong to the oxazoli-
dinones category) but is resistant to other agents, is a PDR
strain. An isolate that is just sensitive to linezolid and is
resistant to all other agents, is an XDR isolate (and also
PDR) and an isolate that is resistant to all agents mentioned
in Table 1, is a PDR isolate (and also MDR and XDR).3 An
antibiotic sensitivity pattern was determined by the Kirby
Bauer’s disc diffusion method on Mueller-Hinton agar. The
MIC method, based on the E-test method, for confirmation
of vancomycin resistance in VRE isolates was used.
All antimicrobial disks used for susceptibility testing were
obtained from (BD: Becton, Dickinson Company, USA).
Enterococcus faecalis (E. faecalis) ATCC 29212 and E. fae-
cium ATCC 6569 were used for quality control, as recom-
mended by Clinical and Laboratory Standards Institute
(CLSI). The plates were incubated at 35C for 18 hours. The
degree of isolate susceptibility to each antibiotic was
interpreted as sensitive (S), intermediate resistant (I) or
resistant (R) by measuring the zone diameter of inhibition.
Antimicrobial agents screening
For the antimicrobial potency production assay, a qualita-
tive bioassay was performed using the spot-on-lawn method
as follows: a medium consisting of trypticase soy broth
supplemented with 0.6% yeast extract (TSBYE) without
glucose and 1.5% agar prepared and spotted with 2 mL of
isolated strains, was incubated overnight at 30C for 24
hours. The incubated agar plates were overlaid with a soft-
agar medium seeded with 107/mL different VRE bacteria
and E. faecalis ATCC 29212, that were tested to determine
the VRE antimicrobial spectrum as indicator. For inhibition
area observation the overlaid plates were incubated over-
night and a clear inhibition area of 3 mm in diameter was
reported as positive.
Antimicrobial agents production assay from
fermentation broth by cell-free supernatant
Colonies showing inhibition activity were subcultured into
10 mL of TSBYE medium and incubated at 30C for 24 hours.
Then, the broth cultures were inoculated in a 2 L flask
containing 500 mL TSBYE without glucose and incubated at
30C for 24 hours in a rotary shaker with agitation at
180 rpm. Supernatant in the fermentation broth was sepa-
rated by centrifugation at 13,000 g for 10 minutes at 12C
and adjusted to pH 7 with 5 M NaOH. Supernatant was
exposed to 100C for 5 minutes and then filtered using a
0.45 mm-pore-size filter. Some of this supernatant (20 mL)
was spotted in BHI agar seeded by E. faecalis ATCC 29212 as
the indicator. For control, TSBYE medium without glucose
and bacteria adjusted to pH 7 with 5 M NaOH and exposed
to 100C for 5 min was used.
Effect of BLIS on the hospital-isolated bacteria
The antimicrobial effect of BLIS of the best producer was
investigated on most common hospital-isolated pathogenbacteria, using the spot-on-lawn method as mentioned
above. These isolates were identified using standard
methods on the basis of their morphological, culture, and
biochemical characteristics.
Growth kinetics and BLIS biosynthesis
The maximum BLIS production time in the Enterococcus
strain that showed the best inhibitory effect on growth of
E. faecalis ATCC 29212 as the indicator strain, was esti-
mated using bacterial growth curves, based on a method
described by Mirhosseini et al.6 The antibacterial activity
was calculated using a critical-dilution micromethod, by
assaying serial two-fold dilutions of cell-free culture su-
pernatants against E. faecalis ATCC 29212. As described
above, cell-free culture supernatants were prepared. Two-
fold serial dilutions of the filtrate were made in 100 mL
volumes of TSAEY in a 96-well microtest. Each well was
then incubated with 40 mL of diluted 100-fold E. faecalis
ATCC 29212 overnight culture (final concentration of
approximately 106 CFU/mL). Plates were incubated at 30C
for 18 hours and absorbencies at 630 nm were then
measured using ELISA reader (Bio-Tek Microplate Reader,
Model EL312, Winooski, United States). This method is
based on BLIS activity, expressed in arbitrary units/mL (AU/
mL) that is defined as the highest BLIS dilution showing
complete inhibition of the indicator strain, and was calcu-
lated as the method described by Tahiria et al.9
Effects of pH, heat, degenerative enzymes, and
exposure to UV light on BLIS
Effects of pH, heat, degenerative enzymes, and exposure
to UV light on BLIS activity were tested. To monitor the
changes in antimicrobial activity after these treatments,
the qualitative spot-on-lawn bioassay, as described above,
was used with E. faecalis ATCC 29212 as the indicator. For
investigation of BLIS stability to temperature, pH and
various degenerative enzymes containing proteinase K (pH
7.0), trypsin (pH 7.0) and pepsin (pH 3.0), the method
explained by Mirhosseini et al6 was used. The effect of UV
light on BLIS activity was determined as follows: 10 mL of
filter-sterilized cell-free supernatant, in a sterile Petri dish,
was exposed to UV irradiation at a distance of 25 cm for 5,
10, 15, 20, 25, and 30 minutes. After each time interval,
BLIS activity was analyzed by the critical-dilution micro-
method as mentioned above.
BLIS molecular weight estimation by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
and partial purification
For BLIS isolation and partial purification, the best BLIS
producer was cultivated in TSBYE for 24 hours at 30C and
then purified partially as the method described by Mirhos-
seini et al.6 Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was used for estimation of BLIS
molecular weight. After electrophoresis, the gel was
fixated by treating with 20% isopropanol and 10% acetic acid
for 2 hours. Then, the gel was removed and subdivided into
two parts; one part was tested for antimicrobial activity
Table 2 Antimicrobial effect of bacteriocin-like inhibitory
substance (BLIS) of Enterococcus faecium strain DSH20 on
hospital-isolated bacteria
Pathogenic bacteria (n) Size of haloes (mm)
Pseudomonas aeruginosa (10) 0
Klebsiella (15) 0
Acinetobacter (12) 0
Escherichia coli (20) 0
MRSA (12) 0
VRE strains (29) 3e5
MRSAZmethicillin-resistant Staphylococcus aureus; VREZ
vancomycin-resistant Enterococcus. A clear inhibition area of
3 mm in diameter was evidenced as positive.
Figure 1. Growth curve and bacteriocin-like inhibitory sub-
stance (BLIS) production of Enterococcus faecium strain DSH20
determined at 30C.
374 D. Shokri et al.and the second part was stained with Coomassie Brilliant
Blue, containing the protein standards (low-molecular-mass
range Sigma Marker protein standards).
Identification of BLSI producing isolate
The identification of the best BLSI producing isolate was
initially carried out on the basis of its morphological, cul-
ture, and biochemical characteristics using standard
methods; Bailey and Scott’s Diagnostic Microbiology,8 and
then confirmed using 16S rRNA PCR using DNA extracts with
the universal primers RW01 (50-AAC TGG AGG AAG GTG GGG
AT-30) and DG74 (50-AGG AGG TGA TCC AAC CGC A-30) by the
CinnaGene Company (Tehran, Iran).
Results
Identification of isolates
All of the 273 Enterococcus isolates were obtained from
different clinical samples during 1 year. These isolates were
Gram-positive, coccus-shaped, aerobes, non spore-
formers, tested negative for the catalase enzyme, tested
positive for the presence of PYR and had growth ability on
bile-aesculin agar and 6.5% NaCl media.
Determination of acquired resistance profiles of
Enterococcus spp.
To define the acquired resistance profiles in Enterococcus
isolates, antimicrobial categories and agents were used as
in Table 1. Among 273 Enterococcus isolates, 212 (77.7%)
were MDR, and were sensitive to meropenem, vancomycin,
ampicillin, daptomycin, linezolid, quinupristin-dalfopristin
and tigecycline but were resistant to other agents. In
addition, among 273 Enterococcus isolates, 29 isolates were
VRE, of which 27 were XDR and two were PDR.
BLIS production assay
Results showed that among the 29 VRE strains, eight iso-
lates had antimicrobial activity showing large inhibition
zones against E. faecalis ATCC 29212 as the indicator
strain. One of these isolates identified as E. faecium strain
DSH20 based on its phenotypical and biochemical proper-
ties, as well as its 16S rRNA gene sequence, had potent
BLIS production against all other 29 VRE strains, in addition
to the indicator strain. The BLIS production was confirmed
in the neutralized supernatant of this isolate (data not
shown).
Effect of BLIS on the hospital-isolated bacteria
Different hospital-isolated bacteria containing Pseudo-
monas aeruginosa (P. aeruginosa) (10 strains), Klebsiella
spp. (15 strains), Acinetobacter spp. (12 strains),
methicillin-resistant Staphylococcus aureus (MRSA) (12
strains) and Escherichia coli (E. coli) (20 strains) were iso-
lated from different patients’ samples in the microbiology
section of Alzahra Hospital (Isfahan, Iran). Thesepathogenic bacteria were identified as the essential iden-
tification tests on the basis of their morphological, culture,
and biochemical characteristics (data not shown). Results
shown in Table 2 demonstrated that BLIS of E. faecium
strain DSH20 had no activity against Gram-negative bacte-
ria containing P. aeruginosa, Klebsiella, Acinetobacter, and
E. coli. In addition, no activity against MRSA strains was
seen.
Growth kinetics and maximum bacteriocin
biosynthesis
The growth curves and the profiles of BLIS production of
the E. faecium strain DSH20 are shown in Fig. 1. BLIS
production was started in the mid-exponential phase of
growth, and the maximum level (3000 AU/mL) was found at
the late-stationary phase of growth. This strain exhibited
the maximum antimicrobial activity against E. faecalis
ATCC 29212 as the indicator strain after 31 hours of incu-
bation at 30C.
Sensitivity of BLIS to pH, heat, degenerative
enzymes, and exposure to UV light
Antimicrobial activity of Enterococcus faecium strain DSH20
was stable under heat and acidic/basic treatment, but was
inactivated by proteinase K, pepsin, and trypsin enzymes
Table 3 Effect of different treatments on activity of
bacteriocin-like inhibitory substance (BLIS) isolated from




Proteinase K, pepsin, and trypsin 0
Heat
60C for 30 min 100
100C for 10 and 20 min 100
100C for 45 min 90







10, 20, and 30 min 100
Figure 3. The sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) of bacteriocin-like inhibitory sub-
stance (BLIS) overlaying with Enterococcus faecalis ATCC 29212
as the sensitive indicator organism showed a clear inhibition
zone after 24 hours at 30C.
BLIS active against VRE 375confirmed by the results of the spot-on-lawn bioassay,
showing their proteinaceous nature. The BLIS was active
after 30 minutes of exposure to UV light. Results are shown
in Table 3.
Estimation of BLIS molecular weight
Partially purified BLIS molecular weight was evaluated by
SDS-PAGE, as shown in Fig. 2. The gel stained with Coo-
massie Brilliant Blue showed protein bands and the mo-
lecular weight of partially purified BLIS from E. faecium
strain DSH20 was estimated to be approximately 35 kDa
(Fig. 2). In addition, the SDS-PAGE of BLIS, overlaid with E.Figure 2. Sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) of partially purified bacteriocin-like
inhibitory substance (BLIS) from Enterococcus faecium strain
DSH20 after staining with Coomassie Brilliant Blue showed the
molecular weight of approximately 35 kDa. Line 1 shows a
molecular mass marker (in kDa) and lines 2 and 3 show a mo-
lecular mass marker of purified BLIS with two repeats.faecalis ATCC 29212 as the sensitive indicator organism,
showed a clear inhibition zone after 24 hours at 30C
(Fig. 3).Discussion
Enterococci are prominent bacteriocin producers due to
production of diversity bacteriocins (enterocins).10e12 They
produce a wide group of structurally diverse antimicrobial
peptides, some of which are atypical and different from
known bacteriocins.10 Many bacteriocins from Enterococcus
have been purified and genetically characterized; most of
them have been obtained from E. faecalis or E. fae-
cium.10e16 For example, Izquierdo et al,10 showed that
E. faecium IT62 produces three different bacteriocins,
EntL50A, EntL50B, and EntIT. Birri et al,12 isolated
bacteriocin-producing E. avium isolates, and a new
pediocin-like bacteriocin (termed avicin A) was purified and
characterized. Nilsen et al,15 isolated a novel antimicrobial
protein, designated enterolysin A from an E. faecalis
LMG2333 culture that inhibits growth of selected entero-
cocci, pediococci, lactococci, and lactobacilli. Kang and
Lee,13 isolated E. faecium GM-1 produces a new bacteriocin
that has a broad antibacterial spectrum including both
Gram-positive and Gram-negative bacteria. Nascimento
et al,14 investigated the antimicrobial activity of E. faecium
FAIR-E 198 against Bacillus cereus, Listeria monocytogenes,
and Staphylococcus aureus. Zendo et al,17 reported
bacteriocin production by E. mundtii QU2 that inhibited the
growth of various indicator strains, including Enterococcus,
Lactobacillus, Leuconostoc, Pediococcus, and Listeria.
Despite these wide studies about bacteriocins produc-
tion in Enterococcus isolates, there are rare studies about
bacteriocins production in Enterococcus that have broad
spectrum activity against PDR strains of VRE; there are no
antibiotics for the treatment of these strains. Recent
emergence of these pathogen bacteria has become a major
clinical problem mobilizing the search for new potent
antimicrobial agents.1,2 Aunpad and Na-Bangchang11
376 D. Shokri et al.isolated pumilicin 4, a novel bacteriocin from Bacillus
pumilus strain WAPB4 with anti-MRSA and anti-VRE activity,
and Yamashita et al,16 isolated bacteriocin 51 (Bac 51) from
vancomycin-resistant E. faecium VRE38 that was active
against E. faecium, E. hirae, and E. durans. In this study,
Enterococci were isolated from different clinical samples
and screened for broad spectrum bacteriocin production.
One Enterococcus isolate identified as E. faecium strain
DSH20 had potent BLIS production against all tested VRE
strains, in addition to the indicator strain.
BLIS produced by E. faecium strain DSH20 inactivated by
proteinase K, pepsin, and trypsin enzymes, provided evi-
dence for its proteinaceous nature, showed stability at a
wide range of pH values from pH 3.0e9.0 at 30C, was heat
stable even after heating at 100C for 5 minutes and kept at
75% in autoclave conditions (121C for 15 minutes). In
addition, the BLIS retained its activity after 30 minutes of
exposure to UV light, which is the first report for this
isolate. During the stationary phase of growth, the
maximum levels of antimicrobial activity were determined
according to findings by others.1,6
The molecular weight of this BLIS was approximately
35 kDa. Some other bacteriocins produced by strains from
the Enterococcus genus, like pumilicin 4 isolated by Aunpad
and Na-Bangchang,11 as determined by mass spectrometry,
was 1994.62 Dalton, have molecular weights ranging be-
tween 7 and 20 kDa and therefore most of these reported
bacteriocins have molecular masses lower than that of our
BLIS. This BLIS seems to be is a novel BLIS with a high mo-
lecular weight and it needs further identifying using a
method such as MALDI-TOF; the potential gene encoding
this BLIS needs to be provided.
Ideal physicochemical properties of this BLIS and its
broad range of activity against VRE isolates, strongly sug-
gests its use in preserving a wide range of foods or in
pharmaceutical compositions that require heating during
preparation, and as an alternative antibacterial agent for
treatment of drug-resistant strains of VRE infection.
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